For children with acute lymphoblastic leukemia (ALL), measurable residual disease (MRD) after the end of first consolidation (EOC) can be used to predict the need for subsequent MRD measurements, according to a study published online Sept. 10 in Leukemia.
This article was originally published on MedicalXpress.com